EICHOR
● Active Not Recruiting
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Condition: Fallopian Tube Mucinous Adenocarcinoma · Ovarian Seromucinous Carcinoma · Platinum-Refractory Fallopian Tube Carcinoma · Sponsor: National Cancer Institute (NCI)
About this study
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (392)
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | — |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | — |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | — |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | — |
| Katmai Oncology Group | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | — |
| CTCA at Western Regional Medical Center | Goodyear, Arizona, United States | — |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | — |
| Mercy Hospital Fort Smith | Fort Smith, Arkansas, United States | — |
+ 380 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04739800